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ABSTRACT
Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory
or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk
between AML cells and the BM stroma is a major mechanism underlying therapy resistance in AML.
Lenalidomide and pomalidomide, a new generation immunomodulatory drugs (IMiDs), possess pleio-
tropic anti-leukemic properties including potent immune-modulating effects and are commonly used in
hematological malignances associated with intrinsic dysfunctional BM such as myelodysplastic syn-
dromes and multiple myeloma. Whether IMiDs may improve the efficacy of current standard treatment
in AML remains understudied. Here, we have exploited in vitro and in vivo preclinical AML models to
analyze whether IMiDs potentiate the efficacy of AraC/Idarubicin-based standard AML chemotherapy by
interfering with the BM stroma-mediated chemoresistance. We report that IMiDs do not exert cytotoxic
effects on either non-del5q/5q- AML cells nor BM-MSCs, but they enhance the immunomodulatory
properties of BM-MSCs. When combined with AraC/Idarubicin, IMiDs fail to circumvent BM stroma-
mediated resistance of non-del5q/5q- AML cells in vitro and in vivo but induce robust extramedullary
mobilization of AML cells. When administered as a single agent, lenalidomide specifically mobilizes non-
del5q/5q- AML cells, but not healthy CD34+ cells, to peripheral blood (PB) through specific down-
regulation of CXCR4 in AML blasts. Global gene expression profiling supports a migratory/mobilization
gene signature in lenalidomide-treated non-del5q/5q- AML blasts but not in CD34+ cells. Collectively,
IMiDs mobilize non-del5q/5q- AML blasts to PB through CXCR4 downregulation, but fail to potentiate
AraC/Idarubicin activity in preclinical models of non-del5q/5q- AML.
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Introduction
Acute myeloid leukemia (AML) comprises a biologically and
genetically heterogeneous group of disorders characterized by
the rapid expansion of immature myeloid blasts in bone marrow
(BM).1,2 In contrast to acute lymphoblastic leukemia (ALL),
treatment of AML has not improved substantially over the last
two decades and many patients still fail to respond to standard
intensive chemotherapy based on nucleoside analogs such as
cytarabine (AraC) or fludarabine and anthracyclines such as
idarubicin and daunorubicin.3,4 Failure of current therapies to
eradicate leukemia-initiating/propagating cells (LICs) and
chemotherapy refractoriness are the major mechanisms under-
lying AML progression/relapse. In addition, the BM stroma has
been involved in the pathogenesis of a variety of hematologic
malignances including AML.5 The interaction of AML cells with
the BM microenvironment in functional niches is a major
mechanism underlying leukemia maintenance and therapy
resistance.5,6 Thus, the high rate of mortality/morbidity and
chemo-resistance in AML guides the search for new compounds
with higher efficiency and lower toxicity.
New generation of immunomodulatory drugs (IMiDs)
such as lenalidomide and pomalidomide are thalidomide ana-
logs, which possess pleiotropic anti-leukemic properties
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including anti-proliferative, anti-angiogenic but also immune-
modulating effects.7-9 They are approved by the Food and
Drug Administration (FDA) and the European Medicines
Agency (EMA). Lenalidomide is approved for both 5q- mye-
lodysplastic syndrome (MDS) and multiple myeloma (MM)
whereas pomalidomide is approved for MM, which are hema-
tological malignances associated with intrinsic dysfunctional
BM.10,11 Some studies reported that lenalidomide has modest
(pre)-clinical activity in lymphoma and AML with manage-
able toxicity.9,12,13 Ongoing Phase I clinical trials assaying
low- and high-dose lenalidomide for both newly diagnosed
and relapsed/refractory AML also support that lenalidomide
displays modest activity when given either alone or combined
with cytarabine and anthracyclines.14
Whether and how IMiDs may benefit current standard treat-
ment in AML needs further investigation. To bring IMiDs to the
forefront of AML therapeutic arsenal, a better understanding of its
mechanism of action in AML is required. In fact, it has recently
been shown that BM mesenchymal stromal cells (BM-MSCs)
derived from diagnostic AML patients are potent immunomodu-
lators and provide similar chemoprotection of AML cells to
cytarabine/idarubicin than normal BM-MSCs.5 Although IMiDs
may have an anti-proliferative effect on leukemic cells, they may
likely exert pleiotropic and immunomodulatory effects at the
stroma-leukemic cell crosstalk, thus improving standard AML
intensive chemotherapy by either potentiating AraC/anthracy-
cline efficacy or reducing BM-MSC-derived chemoresistance.
Here, we have exploited in vitro and in vivo AML preclinical
models to analyze whether IMiDs potentiate the efficacy of
AraC/Idarubicin-based standard chemotherapy by lowering
the BM stroma-mediated chemoresistance. Lenalidomide and
pomalidomide are not cytotoxic for either non-del5q/5q- AML
cells or BM-MSCs, but they enhance the immuno-modulatory
capacity of BM-MSCs.When administered alone or in combina-
tion with AraC and Idarubicin, IMiDs fail to circumvent BM
stroma-mediated resistance of non-del5q/5q- AML cells in vitro
and in vivo but induce robust mobilization of non-del5q/5q-
AML cells, but not healthy CD34+ cells, to peripheral blood (PB)
and spleen likely through specific downregulation of CXCR4 in
AML blasts. Global gene expression profiling supports a migra-
tory/mobilization gene signature in lenalidomide-treated AML
primary blasts. We conclude that IMiDs mobilize non-del5q/5q-
AML blasts to PB through downregulation of CXCR4 but do not
improve AraC/Idarubicin activity in a preclinical model of AML.
Material and methods
AML cell lines and primary leukemic and healthy cells
HL60 and MOLM-13 cells (kindly provided by Prof.
Luciano Di Croce, CRG, Barcelona and Prof Michael
Andreeff, MD Anderson, Houston, TX, respectively) were
cultured as in RPMI medium supplemented with 10% fetal
calf serum (FCS) and antibiotics (Gibco). Patient AML
samples (>90% of blasts) were obtained from fresh BM
from the Hospital Clínico San Carlos (Madrid, Spain) and
Hospital Virgen del Rocío (Seville, Spain). AML diagnosis
was based on French-American-British (FAB)15 and World
Health Organization (WHO) classifications,16,17 Table 1,
summarizes patient’s main clinical/cytogenetic/molecular
characteristics. Fresh peripheral blood (PB) and cord blood
(CB) units were obtained from healthy donors from the
Catalonia Blood Tissue Bank following the institutional
guidelines approved by our local Institutional Review
Board. G-SCF-mobilized PB and BM were obtained from
clinical leftovers from the Hospital Clínic of Barcelona
(HCB). PBMCs were isolated using Ficoll-Paque Plus (GE
Healthcare) density gradient centrifugation, and CD34+
cells were MACS-purified using the human CD34
MicroBead kit and the AutoMACS device (Miltenyi Biotec,
Madrid, Spain) as reported.18,19 The purity of the CD34+
fraction was assessed and was consistently >95%. Primary
AML and CD34+ cells were cultured in Stemspam medium
(Stem Cell Technologies, Vancouver, Canada) supplemented
with the hematopoietic cytokines Stem Cell Factor (100 ng/
mL), FLT3 ligand (100 ng/mL), IL3 (10 ng/mL, all from
PeproTech) and antibiotics (Gibco). BM-MSCs were
obtained, grown and characterized as extensively described
by our group.5,20 Cultures were maintained in a humidified
atmosphere with 5% CO2 at 37⁰C. The study was IRB-
approved by the HCB (HCB/2014/0687) and samples
received upon signed informed consent.
Table 1. Biological and cytogenetic-molecular characteristics of blasts from diagnostic AML patients.
Patient ID Diagnostic Cytogenetics Molecular
Age
(years) Gender Blasts (%)
AML#1 AML-M4 46, XX FLT3-ITD, NPM1MUT 52 F 81
AML#2 AML-M7 46, XX, 20% 47, XX, +8 t(8;21) AML1-ETO 1 F 52
AML#3 AML-M0/
M1
46, XY - 9 M 86
AML#4 AML 46, XY, del(7)(q22) - 61 M 87
AML#5 AML-M4 46, XY FLT3-ITD, NPM1MUT 48 M 80
AML#6 AML 46–47, XY, t(12;13) BCR-ABL (Ph+) 60 M 37
AML#7 AML 46, XY - 43 M 60
AML#8 AML-M5 46, XY - 47 M 54
AML#9 AML-M5a 46, XX, 92,3% 47, XX, +8, +i(8)(q10) x2, t(8;21), t(9;11)(q22;q23) AML1-ETO, MLL1-AF9,
ABL+,WT-1+
6 F 95
AML#10 AML-M2 44, XX, del(5)(q13q33), −7, del(13)(q12q14), −15[20] - 87 F 40
AML#11 AML 45, X, -Y, del(5)(q13q33), 3 ~ 8dmin[7]/44, idem, −12, der(17)t(12;17)(q11;p11),
3 ~ 34dmin[11]/46,XY[2]
- 73 M 71
AML#12 AML 44, XX,del(5)(q13q33), −7, del(13)(q12q14), −15[20] - 79 F 39
AML#13 AML-M4 46, XY, del(3)(q21)[26]/46, idem, del(5)(q22)[3]/46, XY[1] FLT3-ITD, WT-1+ 16 M 75
M, male; F, female; dmin, double minute chromosome; -, no mutations found for FLT3, NMP1, cEBPα, WT and IDH1.
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Drugs
AraC (Cytarabine®, Pfizer), idarubicin (Zavedos®, Pfizer) and
the CXCR4 antagonist AMD3100 (Sigma) were reconstituted
with PBS. Lenalidomide and pomalidomide were kindly pro-
vided by Celgene Corp (San Diego, CA), reconstituted in
DMSO as per supplier´s guidelines and stored in aliquots
at −20⁰C.
Cytotoxicity and apoptosis assays
The cytotoxic effect of the different drugs on HL-60 and
MOLM-13 cell was assessed using Cell Counting Kit-8
based on monosodium salt WST-8 according to the manu-
facturer’s protocol (Sigma-Aldrich). Briefly, 5.000 cells were
plated in 96-well plate and incubated with increasing con-
centrations of the corresponding drug for 48h. After incu-
bation time, absorbance was measured at 450 nm using a
microplate reader. The cytotoxic effect of IMiDs on BM-
MSCs was assessed using MTT assays as previously
described.21,22 Briefly, 2 × 104 cells were cultured with
increasing drug concentrations in 96-well plates for 48 h.
To determine the chemoprotective effect of BM-MSCs a
total of 2 × 104 BM-MSCs were plated in 96-well plates
18 h before addition of AML cells (2 × 104 for cell lines and
2 × 105 for primary cells). BM-MSC:AML co-cultures were
treated with IC25 concentrations of the AraC (77nM) and
Idarubicin (7nM) and 10 µM of lenalidomide/pomalido-
mide for 48–72 h. Apoptosis of CD33+ AML cells was
measured using the annexin-V/7-AAD apoptosis detection
kit (BD Biosciences) on a FACSCanto-II cytometer using
FACSDiva software (BD Biosciences) as previously
described.23
Immunosuppressive assays and cytokine detection
The effect of IMiDs on the BM-MSC-mediated immunosup-
pressive properties and cytokine release (TNFα, IL1β, IL10,
IL6 and SDF1) was determined by CSFE and Luminex
Multiplex assays as previously described.5,24,25
FACS analysis of CXCR4 and SDF1
CXCR4 expression was determined in AML and CD34+ cells
treated with IMiDs. A total of 0.2 × 106 (for cell lines) or
1 × 106 (for primary cells) cells were incubated with 10 µM of
IMiDs (the CXCR4 antagonist AMD3100 was used as a posi-
tive control). Seven days later (48 h–72 h for primary AML
cells) treated cells were stained with anti-human CD45-APC.
Cy7, CD33-APC, CD34-PECy7 and CD184-BV421 (BD
Biosciences) and the mean fluorescence intensity (MFI) of
CD184 within the blast population (CD45+CD33+) was
FACS-quantified using a FACS Canto II cytometer. The
expression of the CXCR4 ligand SDF1 was analyzed in BM-
MSC (0.5 x 106) 48 h after treatment with 10 µM IMiDs. BM-
MSCs were trypsinized and stained with anti-human
CXCL12/SDF-1 (R&D Systems) using the Cell
Permeabilization Kit (FIX&PERM®).26
NSGmice xenotransplantation and analysis of engraftment
All experimental procedures were approved by the Animal
Care Committee of The Barcelona Biomedical Research Park
(HRH-16–0037). Eight-to-14-week-old NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice housed under patho-
gen free conditions were used. In order to recapitulate a BM
stroma milieu, 1 × 105 HL60 (n = 31 mice) or MOLM-13
(n = 33 mice) cells were intra-BM transplanted into non-
irradiated NSG mice together with 3 × 105 irradiated BM-
MSCs.25,27 HL60 AML grafts were monitored by BM aspira-
tion and mice were randomized into treatment groups when
graft was >1% in the contralateral BM (~2–3 weeks post-
transplant). For MOLM-13 AML grafts, mice were rando-
mized for treatment 3 days after intra-BM transplant due to
its aggressiveness. At the end of the treatment period, mice
were sacrificed and cells from the BM, spleen and PB were
stained with anti-human HLA-ABC-FITC, CD33-PE and
CD45-APC (BD Biosciences) to analyze human leukemic
engraftment by flow cytometry. Similarly, healthy CD34+
HSPCs (0.1 × 106 cells) were intra-BM-transplanted into sub-
lethally irradiated (2.25 Gy) NSG mice (n = 10) together with
3 × 105 irradiated BM-MSCs. Six weeks later, when human
healthy chimerism was evident, mice were treated with lena-
lidomide. At the end of lenalidomide treatment, mice were
sacrificed and cells from the BM, spleen and PB were stained
as above to analyze human normal chimerism by flow cyto-
metry. Multilineage engraftment was assessed using CD33-
APC, CD19-PE and CD34-PE.Cy7 (BD Biosciences). Spleen
infiltration of AML cells was analyzed by immunohistochem-
istry using an anti-human-CD45.
In vivo chemotherapy and imids treatment
Ara-C and idarubicin were administrated following a well-
established 5 + 3 treatment schedule, consisting on intrave-
nous (i.v.) co-delivery of 30 mg/Kg of Ara-C and 0.1 mg/Kg
of idarubicin for 3 days followed by intraperitoneal injection
(i.p.) of Ara-C for two further days (A + I treatment).28
Lenalidomide (25 mg/kg) given as single agent was admini-
strated i.p. for 10 days. When combined with A + I treat-
ment, lenalidomide (25 mg/kg) was administrated alone
during days 1–3 and 9–10 and with A + I on days 4–8. 1%
DMSO/PBS solution was always used as vehicle treatment.
Mice were weighted throughout treatment and drug doses
were recalculated as necessary.
Microarray gene expression profiling (GEP)
Non-del5q/5q- AML primary samples (n = 3) and BM-CD34+
HSPCs (n = 2) were FACS purified (CD45+CD33+ purity >98%)
and cultured with 10 µM lenalidomide for 48h before global gene
expression profiling (GEP) as described.29 Total RNA was then
extracted using a Maxwell® RSC simplyRNA Cells Kit in a
Maxwell® RSC Instrument (Promega) and its quality checked in
the Agilent 2100 Bioanalyzer. Total RNA samples were labeled
with Cy3 using the Quick-Amp Labeling Kit and hybridized with
the Gene Expression Hybridization Kit to the GeneChip Human
Gene 2.0 ST (Affymetrix) following Manufacturer’s instructions.
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Hierarchical clustering of genes was performed with the one
minus correlation metric and the unweighted average distance.
Only genes showing >1.5-fold change expression and
p-value<0.05 were considered differentially expressed and were
subjected to gene ontology (GO) term analysis using Gorilla30,31
publicly available at http://cbl-gorilla.cs.technion.ac.il. Microarray
data were deposited in the public Gene Expression Omnibus
database, accession number GSE106748.
Results
BM stroma/milieu confers resistance of AML cells to
AraC/idarubicin
Chemotherapy based on the combination of Ara-C with
anthracyclines, either idarubicin or daunorubicin, is the
first-line induction treatment in diagnostic AML.3,4 Here,
viability in vitro assays revealed that both cytotoxic drugs,
Ara-C and idarubicin, are equally toxic in different AML
cell lines with an IC50 of ~10
−7M (Fig 1S). Exposure to Ara-
C plus idarubicin (Ara-C/Ida) resulted in 80%–95% cell death
of AML cell lines, measured by Annexin V staining
(Figure 1A). However, when co-cultured with BM-MSCs,
AML cell lines were chemo-resistant with only 40–50% cell
death (Figure 1A). To further test whether the BM stroma/
milieu protects AML cells from Ara-C/Ida treatment, AML
cell lines were co-transplanted via intra BM transplant
(IBMT) into NSG mice with human BM-MSCs which largely
increase AML engraftment (Fig 2S), as reported in several
hematologic malignances.32-35 When engraftment was >1%
in non-injected tibia, mice were treated with Ara-C/Ida admi-
nistrated following the well-established 5 + 3 treatment
schedule.28 Similar to the in vitro results, Ara-C/Ida signifi-
cantly (2-3-fold) reduced AML engraftment/survival in
Figure 1. BM microenvironment protects HL60 and MOLM-13 cells from AraC+Idarubicin-based chemotherapy in vitro (A) and in vivo (B). (n = 3). *p < 0.05. **p < 0.01.
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extramedular BM hematopoietic tissues and in contralateral
BM (CL) whereas the co-transplanted human BM-MSCs con-
ferred chemoresistant to AML cells in injected tibia (IT)
(Figure 1B).
Imids exert no toxicity on non-del5q/5q- AML cells but
increase immunosuppressive properties of BM-MSCs
The immune-modulating properties of BM stroma/BM-
MSCs are a major mechanism underlying BM stroma-
mediated chemoresistance in hematological malignances.5
Lenalidomide and pomalidomide possess pleiotropic anti-
tumor properties including also tumor-controlling immune-
modulating effects in other hematological BM malignances
such as MDS and MM.9-11 We therefore set out to assess
the anti-leukemia effects of lenalidomide and pomalidomide
in AML. Strikingly, as single agents, lenalidomide and
pomalidomide display no cytotoxic effects (assayed at 48h
and 72h after drug exposure) on neither AML cell lines
(Figure 2A) nor diagnostic primary AMLs (n = 9) covering
different cytogenetic/molecular AML subtypes other than
del5q/5q- AMLs (Figure 2A, Table 1). Importantly, despite
lenalidomide/pomalidomide had neither cytotoxic effects on
BM-MSCs (Figure 2A) they did enhance the immunosup-
pressive capacity of BM-MSCs (Figure 2B). In fact, IMiDs
boosted the BM-MSC-mediated inhibition of activated T
cells (Figure 2B) through blocking T-cell release of pro-
inflammatory cytokines such as TNFα and IL1β while
enhancing the production of the master anti-inflammatory
cytokine IL10 (Figure 2B). Lenalidomide/pomalidomide also
inhibited the release of the pro-inflammatory cytokine IL6
by BM-MSC (Figure 2C). The potent immune-modulatory
properties of IMiDs on BM-MSCs24 led us to combine
IMiDs with Ara-C/Ida-based standard AML treatment as a
potential therapeutic approach to bypass the BM-MSC-
mediated chemoresistance to Ara-C/Ida.
Imids fail to overcome BM-MSC/stroma-mediated
chemoresistance of non-del5q/5q- AML cells but induce
specific mobilization of AML cells to PB
Neither lenalidomide nor pomalidomide were unable to over-
come the BM-MSC-mediated resistance of non-del5q/5q-
AML cells to Ara-C/Ida chemotherapy either in vitro
(Figure 3A) or in vivo (Figure 3B). Surprisingly, when lenali-
domide was combined with chemotherapy we observed a
robust (3–4-fold) mobilization of non-del5q/5q- AML cells
into extramedular BM hematopoietic sites including PB and
spleen (Figure 3B). Next, we performed similar in vivo experi-
ments by treating AML-engrafted NSG mice with lenalido-
mide as single agent and confirmed that it induces a robust
mobilization of non-del5q/5q- AML cells into PB (Figure 4A)
and spleen (Figure 4B).
Specific mobilization of leukemic cells from BM to PB is
commonly desirable in the clinical setting because circulat-
ing blasts are more sensitive to treatment in part due to
their detachment from the chemoprotective BM niche.4,36,37
However, mobilization of normal hematopoietic stem/pro-
genitor cells (HSPCs) to PB is not desired because it would
accelerate BM aplasia and subsequent hematopoietic
defects. Thus, we next analyzed whether lenalidomide also
mobilizes normal HSPCs to PB. CB CD34+ cells were IBM-
transplanted in NSG mice and total (CD45+HLA-ABC+)
and immature (CD45+HLA-ABC+CD34+) engraftment was
analyzed 6–7 weeks later. Interestingly, lenalidomide failed
to mobilize normal HSPC indicating that lenalidomide-dri-
ven mobilization into PB is specific for AML cells
(Figure 4C).
Lenalidomide-mediated mobilization of AML cells to PB is
associated to downregulation of CXCR4 and a migratory
transcriptomic signature in AML cells
We next sought to gain insights into the mechanisms under-
lying lenalidomide-mediated mobilization of AML cells.
Clearly, the CXCR4/SDF1 axis plays a major role in the
interaction of HSPCs and leukemic cells within BM niches.
CXCR4 is highly expressed in HSPCs/leukemic cells whereas
SDF1 is a cytokine commonly released by BM-MSCs,37,38
(Figure 5A). Consequently, we first treated both AML cell
lines and primary non-del5q/5q- AML blasts with lenalido-
mide and pomalidomide and found a significant (25%–50%)
reduction in the levels of CXCR4 in AML cells similar to
treatment with the specific CXCR4 inhibitor AMD3100
(Figure 5B). In line with the IMiDs-mediated specific mobi-
lization of AML blasts (Figure 4), we confirmed that lenali-
domide/pomalidomide do not down-regulate CXCR4
expression in healthy PB- or BM-derived HSPCs
(Figure 5B). In contrast, lenalidomide and pomalidomide
treatment did not impact the either expression levels or
cytokine release of SDF1 by human BM-MSCs (Figure 5C).
Together, these results suggest that IMiDs specifically med-
iate the mobilization of AML cells to PB through down-
regulation of CXCR4.
To identify patterns of gene expression that might provide a
molecular explanation for the IMiDs-induced mobilization of
AML cells, we performed whole-genome GEP in lenalidomide-
treated versus DMSO-treated AML blasts (blast purity>95%,
n = 3 de novo non-del5q/5q- AMLs). A heatmap representation
of hierarchical clustering of genes differentially expressed (1.5-
fold regulation, p-value<0.05) between lenalidomide- versus
DMSO-treated AML cells is represented in Figure 6A. A total
of 323 genes were differentially expressed between lenalido-
mide- and DMSO-treated AML cells. Of these, 196 (61%)
were upregulated and 127 (39%) downregulated in lenalido-
mide-treated AML cells, establishing a lenaledomide-specific
transcriptomic signature. To get insights into the biological
functions affected by differentially expressed genes, we used
the Gorilla software,30,31 and found that many significant bio-
logical processes predicted to be activated in the lenalidomide-
treated AML cells were associated with “migration/motility/
mobilization/chemotaxis” (Figure 6A). In contrast, exposure
of CB-CD34+ HSPCs to lenalidomide did not affect such bio-
logical functions (Figure 6B). This lenalidomide-induced tran-
scriptomic signature supports a CXCR4-mediated mechanism
underlying the mobilization of non-del5q/5q- AML cells to PB
in response to IMiDs.
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Figure 2. Effects of IMiDs on primary AML blasts and BM-MSC. (A) Lenalidomide and pomalidomide do not have a cytotoxic effect on either AML cell lines (n = 3)
(top panel), primary AML blasts (n = 9, bottom left panels) or BM-MSC (n = 3) (right bottom panels). (B) Left panel: IMiDs potentiate the immunosuppressive effect of
BM-MSCs, measured as percentage of CFSE+ non-proliferating cells. CSFE-labeled PBMCs were stimulated with PHA and then co-cultured with BM-MSCs in the
presence of lenalidomide or pomalidomide for 5 days (n = 3). Middle panels: representative flow-cytometry histograms of cycling (CSFElow) PBMCs. Right panels:
Concentration of the indicated cytokines in cell-culture supernatants determined by Luminex Multiplex assays. PBMCs were co-cultured with BM-MSCs in the
presence/absence of IMiDs. Error bars indicate the SEM values of the n = 3 biological replicates. (C) IMiDs diminish IL6 production by BM-MSC (n = 3). *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.
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Figure 3. IMiDs combined with AraC-Idarubicin do not circumvent BM- microenvironment-mediated resistance of AML cells but induce robust extramedullary mobilization of
AML cells. (A) Lenalidomide and pomalidomide do not overcome BM-MSC-mediated resistance of AML cell lines to intensive chemotherapy (n = 3). (B) IMiDs combinedwith AraC
+Idarubicin highly mobilize AML blasts to PB and spleen in AML xenograft models (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Lenalidomide overcomes BM-MSC/stroma-mediated
chemoresistance of AML cells from del5q/5q- patients
A phase II clinical trial has recently reported promising results
for lenalidomide combined with AraC/daunorubicine in both
MDS and AML patients with 5q alterations (del5q/5q-).39
Thus, we next focused our efforts on this cytogenetic sub-
group of AML patients as potential candidate patients
benefiting from the combination of IMiDs with AraC/idaru-
bicine. Primary cells from del5q/5q- AML patients were trea-
ted with lenalidomide, AraC/Ida or their combination for
48-72h, in the presence/absence of BM-MSCs (Figure 7A).
Opposite to non-del5q/5q- AML cells (Figure 2A), lenaledo-
mide used as single agent displayed a slight, but consistent,
20% toxicity in del5q/5q- AML cells (Figure 7B). More
Figure 4. When administered as a single agent, lenalidomide highly mobilizes AML cells, but not healthy CD34+ cells, to PB. (A,B) Lenalidomide administered alone
mobilizes AML cells to PB (A) and spleen (B). AML infiltration in PB and spleen was detected by FACS and immunohistochemistry, respectively. (C) Lenalidomide fails
to mobilize healthy CD34+ cells (n = 3). *p < 0.05. **p < 0.01.
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importantly, lenaledomide significantly boosted the toxicity of
del5q/5q- AML cells when combined with AraC/Ida, over-
coming the BM-MSC/stroma-mediated chemoresistance of
AML cells from del5q/5q- patients (Figure 7C). Interestingly,
lenalidomide did not down-regulate CXCR4 expression on
del5q/5q- AML cells (Figure 7D), indicating that
Figure 5. IMiDs mobilizes AML cells to PB through CXCR4 downregulation. (A) Cartoon of the CXCR4-SDF1 crosstalk between leukemic blasts and BM stromal cells. (B) Effect of
IMiDs on the expression levels of CXCR4 in AML cell lines, primary AML cells (top panels), PB-derived CD34+ cells and BM-derived CD34+ cells (bottom panels). (C) Effect of IMiDs
on the expression (Left panel) and production levels (right panel) of SDF1 by BM-MSCs. The specific CXCR4 inhibitor AMD3100 was used as positive control.
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Figure 6. Global GEP reveals a migratory signature in lenalidomide-treated AML blasts. (A, B) Left panels: Heatmap representation of hierarchical clustering of genes
differentially expressed between lenalidomide-treated and untreated AML blasts (n = 3 leukemias) (top panel) and BM-CD34+ cells (n = 2 healthy donors) (bottom
panel). Right panel: Statistically significant biological functions identified using IPA on genes differentially expressed in lenalidomide-treated versus untreated AML
blasts (top panel) and CD34+ cells (bottom panel). They are ranked by z-score. A z-score >2 indicates a predicted activation of that biological function. Biological
functions associated with ‘cell migration/movement/motility’ are shown in black.
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lenalidomide partially overcomes BM-MSC/stroma-mediated
chemoresistance of AML cells from del5q/5q- patients likely
at the expense of blast mobilization.
Discussion
AML represents a clinically and genetically very heteroge-
neous group of diseases characterized by an accumulation of
proliferative, abnormally differentiated hematopoietic cells in
the BM and other tissues, leading to interference of normal
hematopoiesis and BM failure. AML is one of the most com-
mon hematopoietic malignances with ~25.000 new cases per
year in United States and Europe.40 Overall, AML has an
unfavorable clinical outcome, largely determined by age, cyto-
genetic/genetic lesions as well as patient´s initial response to
standard treatment.2 The large genetic/cytogenetic and phe-
notypic heterogeneity together with a median age at diagnosis
of ~65–67 years old have long represented a limitation
towards the development of better treatments.4 Despite
many clinical trials have been conducted over the last two
decades, the standard current treatment in AML remains
unchanged, and relies on intensive induction chemotherapy
based on nucleoside analogs such as Ara-C or fludarabine and
anthracyclines such as idarubicin and daunorubicin followed
by high doses Ara-C consolidation.41 Although complete
remission rates (CRR) of ~80% are commonly achieved with
conventional chemotherapy,4,42 the median survival time is
short and the outcome of relapsed patients is dismal.43-45
Novel agents or better treatment combinations/schedules
with higher efficacy and less toxicity are therefore in high
demand for de novo and relapsed AML.
Failure of current therapies to eradicate LICs and che-
motherapy refractoriness are the major mechanisms under-
lying AML progression/relapse, being in part because the BM
provides a protective microenvironment to support the survi-
val of LICs/bulk leukemic cells, hence promoting drug resis-
tance and influencing clinical outcome. In AML, the high rate
of relapse may in part be a result of the inability of current
treatments to effectively overcome the protective influence of
the BM niche.5,46 In fact, it has been recently shown that BM
mesenchymal stromal cells (BM-MSCs) derived from diag-
nostic AML patients are strong immunomodulators and pro-
vide similar or even higher chemoprotection of AML cells to
cytarabine/idarubicin than normal BM-MSCs.5 Therefore,
new compounds or improved combinatory regimens targeting
the interaction between the BM microenvironment and AML
leukemic cells are very attractive candidates.
The new generation of immunomodulatory drugs (IMiDs)
such as lenalidomide and pomalidomide are thalidomide ana-
logs, which possess pleiotropic anti-leukemic properties
including anti-proliferative, anti-angiogenic but also
immune-modulating effects.7-9 They are approved by the
FDA and EMA for 5q- MDS and/or MM which are hemato-
logical malignances associated with intrinsic dysfunctional
BM with remarkable clinical responses.10,11 However, whether
IMiDs may potentiate current standard treatment in AML
remains an issue of debate. To bring IMiDs to the forefront
of AML therapeutic arsenal, a better understanding of its
mechanism of action in AML cells and in the interphase
Figure 7. Effects of Lenalidomide on primary blasts from patients with del5q/5q- AML. (A) Scheme depicting the experimental design. (B) Lenalidomide toxicity on
primary del5q/5q- AML cells (n = 4). (C) When combined with standard chemotherapy lenalidomide largely overcomes BM-MSC-mediated resistance of del5q/5q-
AMLs to AraC+Idarubicin (n = 4). (D) Effect of lenalidomide on the expression levels of CXCR4 in del5q/5q- AML cells (n = 4). AMD3100 was used as positive control.
*p < 0.05; n.s, no statistical differences.
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tumor-stroma is required. In this study, we hypothesized that
the testing of IMiDs may be facilitated by in vitro and in vivo
assays that model the tumor-BM stroma interactions.47-49
Hence, we used human primary BM-MSCs and intra BM
co-transplantation with AML cells into NSG mice to mimic
the interaction of AML cells with the BM stroma as a platform
to assess whether IMiDs add efficiency to current standard
AML chemotherapy. We report that lenalidomide and poma-
lidomide, when administered as single agents, have cytotoxic
effects on neither non-del5q/5q AML cells nor BM-MSCs,
even at doses as high as 100 µM. This contrasts the anti-
proliferative effects reported for IMiDs in other hematopoietic
malignances, evidencing the immature nature of AML cells
(progenitor-like cells) and the complex biology of AML.9-11
However, IMiDs enhanced the immunomodulatory properties
of BM-MSCs as demonstrated by the suppression activated T
cells proliferation, inhibition of the production of pro-inflam-
matory cytokines including TNFα, IL1β and IL6 and
increased production of the anti-inflammatory cytokine
IL10, suggesting that IMiDs may represent safe candidate
drugs interfering with the protective BM stroma for combina-
tion with current AML chemotherapy.
Unfortunately, when combined with AraC and Idarubicin,
both lenalidomide and pomalidomide fail to circumvent BM
stroma-mediated resistance of non-del5q/5q AML cells in in
vitro and in vivo AML models. The clinical efficacy of lenali-
domide has been explored as either low-dose or high-dose
lenalidomide as monotherapy50-54 and in combination with
azacitidine55,56 for both newly diagnosed and relapsed/refrac-
tory AML. Overall, these clinical trials were somewhat dis-
appointing with CRR as low as 11%–20% and remission
duration below 5–7 months.14 Our preclinical studies
mechanistically support previous modest clinical activity
reported for IMiDs in AML, and discourages future clinical
trials using either lenalidomide or pomalidomide for non-
del5q/5q AML either as monotherapy or polytherapy. Of
note, a recent Phase II clinical study of lenalidomide com-
bined with intensive chemotherapy in AML has reported that
only del5q/5q- AML patients show promising CRR.39 Here,
our pre-clinical studies confirm that lenaledomide used as
single agent displays ~20% toxicity only in del5q/5q- AML
cells and it overcomes BM-MSC/stroma-mediated chemore-
sistance of AML cells exclusively from del5q/5q- patients. A
potential mechanism of action of lenalidomide involves the
degradation of casein kinase 1A1 (CK1α).57 In fact, del5q
MDS patients possess a heterozygous deletion CK1α.58
Collectively, our data is in line with Ades and colleagues39
and suggest that the mechanisms of action of lenalidomide on
AML may depend on cell intrinsic/autonomous genetic
makeup, further pinpointing genetic and biological heteroge-
neity in AML. Despite the overall limited activity of lenalido-
mide during induction/consolidation therapy its efficiency
during AML maintenance therapy has yet to be tested.
Intriguingly, we found that lenalidomide, administered
either as monotherapy or combined with conventional che-
motherapy, induces robust mobilization of non-del5q/5q
AML cells to extramedullary hematopoietic tissues including
PB and spleen, suggesting that IMiDs might function as plerix-
afor, a small molecule inhibitor of the CXCR4/SDF1 axis,
extensively used for chemosensitazion of AML blasts by dis-
rupting the interaction of leukemic blasts with the
environment.4,36,37,59 In fact, lenalidomide mediated the mobi-
lization of AML cells to PB through downregulation of CXCR4
in non-del5q/5q AML cells but does not affect either the
expression or the production of its ligand SDF1 by BM-MSCs.
In contrast to plerixafor, lenalidomide does not mobilize nor-
mal CD34+ HSPCs to PB. Whole-genome GEP revealed a
transcriptomic migratory signature of lenalidomide-treated
non-del5q/5q AML primary blasts but not lenalidomide-treated
CD34+ cells, confirming that the IMiD-mediated mobilization
is specific of AML blasts. We cannot rule out that other signal-
ling pathways/mechanisms contribute to the IMiD-induced
mobilization phenotype. Importantly, in contrast to plerixafor,
IMiDs do not chemosensitize AML blasts to chemotherapy,
further supporting that the addition of IMiDs to cytotoxic
chemotherapy seems not feasible in AML.36,59 Lenalidomide-
attenuated pro-inflammatory cytokines including TNFα, γIFN,
IL1β and macrophage inhibitory factor (MIF) have been pre-
viously described to interact with master pathways/molecules
such as CXCR4-SDF1 axis, collagenases, integrins and eicosa-
noids in controlling cell migration and mobilization.60-63 Thus,
the immunomodulatory effects exerted by IMiDs seem to influ-
ence the BM niche in a way non-del5q/5q AML cells physically
detach from BM stroma. Future in vivo imaging studies will
precisely define the mechanisms underlying the lenalidomide-
mediated AML chemotaxis.
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